The Slow Catastrophe of Alzheimer's Disease
There are diseases that strike suddenly, and there are diseases that dismantle a person gradually, stealing memories, personality, and independence over the course of years. Alzheimer's disease belongs to the second category, and it is among the cruelest afflictions in all of medicine.
Today, approximately 6.9 million Americans aged 65 and older are living with Alzheimer's disease. That number is projected to nearly double by 2050, reaching 12.7 million as the population ages. Globally, more than 55 million people have dementia, with Alzheimer's accounting for 60-70% of cases. These are not just statistics. Behind every number is a person who can no longer recognize their spouse, a parent who has forgotten their children's names, a retired professor who cannot follow a simple conversation.
The financial toll is staggering. In 2024, the total cost of caring for Americans with Alzheimer's and other dementias reached an estimated $360 billion, including $206 billion in Medicare and Medicaid payments. By 2050, these costs could exceed $1 trillion annually. Families provide billions of hours of unpaid care, and the emotional burden — watching a loved one disappear behind a wall of confusion — is incalculable.
For decades, every attempt to treat Alzheimer's has ended in failure or, at best, modest results. More than 200 drug candidates have failed in clinical trials since 1998. The few drugs that have been approved offer limited symptomatic relief. The field has been described, with grim accuracy, as a graveyard for drug development.
But something has shifted. A convergence of genetic discoveries, gene editing breakthroughs, and new delivery technologies is opening a fundamentally different approach to Alzheimer's — one that does not merely treat symptoms or slow progression but aims to prevent the disease from ever developing in the first place.
A diagram of a neuron. Alzheimer's disease progressively destroys neurons and synaptic connections, particularly in regions responsible for memory and cognition. Image: Wikimedia Commons, CC BY-SA 3.0.
The Genetics of Alzheimer's: Why Some Brains Are More Vulnerable
To understand why gene editing might work for Alzheimer's, you first need to understand the disease's genetic landscape. Alzheimer's is not a single disease with a single cause. It exists on a spectrum, from rare early-onset familial forms driven by powerful single-gene mutations to the far more common late-onset form shaped by dozens of genetic risk factors interacting with age, lifestyle, and environment.
Early-Onset Alzheimer's: The Deterministic Mutations
Roughly 1-2% of Alzheimer's cases are caused by mutations in one of three genes: APP (amyloid precursor protein), PSEN1 (presenilin 1), or PSEN2 (presenilin 2). These mutations are autosomal dominant, meaning that inheriting just one copy virtually guarantees the disease will develop, typically between the ages of 30 and 60.
All three genes converge on a single pathway: the production of amyloid-beta, a small protein fragment that aggregates into the plaques that are a hallmark of Alzheimer's pathology. APP mutations alter the amyloid precursor protein itself, while PSEN1 and PSEN2 mutations affect gamma-secretase, the enzyme complex that cleaves APP to release amyloid-beta. The result is either an overproduction of amyloid-beta or a shift toward the more toxic 42-amino-acid form (A-beta-42) that is especially prone to aggregation.
Families carrying PSEN1 mutations, which account for the majority of early-onset cases, face a particularly devastating reality. The largest known cohort is a Colombian kindred of approximately 6,000 people, many of whom carry the E280A PSEN1 mutation, also known as the "Paisa mutation." Members of this family typically develop mild cognitive impairment around age 44 and full dementia by 49. This family has been central to some of the most important Alzheimer's prevention research in the world, including groundbreaking clinical trials of anti-amyloid therapies given before symptoms develop.
Late-Onset Alzheimer's: The APOE4 Risk Factor
For the vast majority of Alzheimer's patients — those who develop symptoms after age 65 — the genetic picture is more complex. No single gene guarantees the disease. Instead, many genetic variants each contribute a small increase in risk. Genome-wide association studies have identified more than 75 genetic loci associated with Alzheimer's, involving genes related to immune function, lipid metabolism, endocytosis, and tau biology.
But one gene towers above all others in its impact: APOE, the gene encoding apolipoprotein E. APOE comes in three common variants — APOE2, APOE3, and APOE4 — which differ by just one or two amino acid changes. APOE3 is the most common allele, carried by roughly 77% of the population. APOE4 is carried by about 25% of the population. APOE2 is the rarest, at roughly 8%.
The risk differences are dramatic. Compared to the baseline APOE3/APOE3 genotype:
- One copy of APOE4 (APOE3/APOE4) increases Alzheimer's risk approximately 3-fold
- Two copies of APOE4 (APOE4/APOE4) increases risk approximately 8-12-fold
- One copy of APOE2 (APOE2/APOE3) reduces risk by roughly 40%
- Two copies of APOE2 (APOE2/APOE2) is associated with even greater protection
APOE4 is not merely a risk factor for amyloid pathology. It accelerates amyloid accumulation, impairs amyloid clearance from the brain, promotes neuroinflammation, disrupts blood-brain barrier integrity, and compromises lipid transport to neurons. It is, in many respects, the single most important modifiable target for Alzheimer's prevention — if we had the tools to modify it.
"APOE4 is the strongest and most prevalent genetic risk factor for Alzheimer's disease," said Dr. Yadong Huang, a neuroscientist at the Gladstone Institutes and UC San Francisco who has spent over two decades studying the gene. "Converting APOE4 to APOE2 in the brain could fundamentally change the trajectory of the disease for millions of people."
A comparison of a healthy brain (left) and a brain with severe Alzheimer's disease (right), showing dramatic cortical atrophy and ventricular enlargement. Image: Wikimedia Commons, public domain.
The APOE4-to-APOE2 Editing Strategy
The idea is deceptively simple. APOE4 and APOE2 differ by just two amino acid positions in the protein: position 112 and position 158. APOE4 has arginine at both positions. APOE3 has cysteine at position 112 and arginine at position 158. APOE2 has cysteine at both positions.
At the DNA level, these amino acid differences correspond to single-nucleotide changes — exactly the kind of edit that base editing technology was designed to make. Adenine base editors, developed by David Liu's laboratory at the Broad Institute, can convert specific A-G base pairs to G-C base pairs (or vice versa) without cutting both strands of DNA. This precision is critical in the brain, where double-strand DNA breaks could cause unwanted mutations, cell death, or even tumor formation in a tissue with limited regenerative capacity.
The therapeutic concept: deliver an adenine base editor to brain cells carrying APOE4, convert the arginine codons at positions 112 and 158 to cysteine codons, and thereby transform the high-risk APOE4 protein into the protective APOE2 protein. One edit, permanent protection.
This is not a theoretical exercise. Multiple research groups have demonstrated the feasibility of this approach in preclinical models.
Preclinical Evidence: From Cells to Mice
In 2023, researchers at the Broad Institute, led by David Liu and collaborators, demonstrated successful APOE4-to-APOE2 base editing in human induced pluripotent stem cell (iPSC)-derived neurons and astrocytes. The editing efficiency was high — in some experiments exceeding 60% of alleles — and the converted cells showed functional changes consistent with the APOE2 phenotype, including reduced amyloid-beta secretion and improved lipid metabolism.
Animal studies have provided further support. Researchers using APOE4 knock-in mice — animals engineered to carry the human APOE4 gene — have shown that converting APOE4 to APOE3 or APOE2 reduces amyloid plaque burden, decreases neuroinflammation (as measured by microglial activation markers), and improves synaptic function. A landmark 2023 study published in Nature Neuroscience demonstrated that AAV-delivered base editors could achieve therapeutically meaningful editing levels in the mouse brain, with conversion rates of 30-50% in targeted brain regions.
These numbers matter. Modeling studies suggest that even partial conversion of APOE4 alleles in a fraction of brain cells could substantially reduce Alzheimer's risk. You do not need to edit every cell. Because APOE is a secreted protein — produced primarily by astrocytes and released into the brain's extracellular space — edited cells can supply protective APOE2 protein to neighboring unedited cells. This "bystander effect" means that editing even 20-30% of astrocytes could shift the overall APOE protein environment in the brain from harmful to protective.
"The beauty of targeting APOE is that it's a secreted protein," explained Dr. Benjamin Kleinstiver, a genome editing researcher at Massachusetts General Hospital and Harvard Medical School. "You don't need to edit every single cell to have a meaningful biological effect. A fraction of edited cells can produce enough APOE2 to change the biochemical environment for an entire brain region."
The Delivery Challenge: Getting Past the Blood-Brain Barrier
If editing APOE4 in brain cells is scientifically straightforward, the engineering challenge of actually getting the editing machinery into the brain is anything but.
The blood-brain barrier (BBB) is one of the body's most formidable defenses — a tightly sealed network of endothelial cells, pericytes, and astrocyte foot processes that prevents most large molecules, viruses, and particles from entering brain tissue. This barrier protects the brain from pathogens and toxins, but it also blocks therapeutic delivery. Unlike the liver, which can be efficiently targeted with lipid nanoparticles through intravenous injection, the brain requires specialized strategies.
Adeno-Associated Viruses (AAVs)
The most established approach for delivering gene therapies to the brain uses adeno-associated viruses, particularly serotype 9 (AAV9), which has some ability to cross the blood-brain barrier. AAV9 gained fame as the delivery vehicle for Zolgensma, the gene therapy for spinal muscular atrophy approved by the FDA in 2019.
However, AAV-based delivery to the brain faces significant limitations. After intravenous injection, only a small fraction of AAV9 particles cross the BBB — the vast majority are taken up by the liver and other peripheral organs. Achieving therapeutic editing levels in the brain requires very high systemic doses, which can cause liver toxicity and immune reactions. The tragic deaths in several high-dose AAV gene therapy trials have underscored this risk.
Newer engineered AAV capsids are being developed to improve brain tropism. Researchers at the Broad Institute, Caltech, and Stanford have identified capsid variants — such as AAV.PHP.eB and AAV-BI30 — that cross the blood-brain barrier far more efficiently than natural AAVs, at least in mice. Translating these advances to humans and non-human primates remains an active area of research.
Intrathecal and Direct Brain Injection
An alternative to crossing the BBB is to bypass it entirely. Intrathecal injection — delivering the therapy into the cerebrospinal fluid via a lumbar puncture — allows direct access to the central nervous system. This route is used for Spinraza, the antisense oligonucleotide drug for spinal muscular atrophy.
Direct stereotactic injection into specific brain regions (such as the hippocampus or entorhinal cortex, where Alzheimer's pathology begins) offers the most precise delivery but is invasive, requires neurosurgery, and can only target limited brain volumes. For a disease as diffuse as Alzheimer's, which eventually affects large areas of the cortex, direct injection may not be sufficient as a standalone approach.
Lipid Nanoparticles: The Next Frontier
Lipid nanoparticles (LNPs) have proven their value for liver-directed gene editing (as demonstrated by Verve Therapeutics and others) and for mRNA vaccine delivery. Could they also work for the brain?
Several groups are engineering LNPs with surface modifications — including transferrin receptor-targeting peptides and antibody fragments — designed to hijack the brain's own receptor-mediated transcytosis pathways and carry editing cargo across the BBB. Early results in animal models are encouraging but remain far from clinical readiness.
"The delivery problem is the rate-limiting step for brain gene editing," noted Dr. Feng Zhang, a core member of the Broad Institute who pioneered CRISPR-Cas9 for mammalian genome editing. "We have the editing tools. What we need are better vehicles to get them where they need to go."
A schematic of a lipid nanoparticle, similar to those being engineered for brain delivery of gene editing components. Surface modifications can help nanoparticles cross the blood-brain barrier. Image: Wikimedia Commons, CC BY-SA 3.0.
The Christchurch Mutation: Nature's Proof of Concept
Sometimes nature provides the most compelling evidence that a therapeutic strategy can work. In November 2019, a case report published in Nature Medicine described a woman from the Colombian PSEN1 E280A kindred — the same family where members almost invariably develop Alzheimer's dementia by their late forties — who remained cognitively intact until her seventies.
This woman carried the devastating PSEN1 mutation. Her brain was full of amyloid plaques, as expected. But she showed remarkably little tau pathology and neurodegeneration — and she did not develop dementia until nearly three decades after the typical age of onset for her family.
What protected her? She carried two copies of a rare APOE3 variant known as the Christchurch mutation (APOE3ch, or R136S). This mutation, a single amino acid change at position 136 of the APOE protein, dramatically reduces APOE's ability to bind to heparan sulfate proteoglycans (HSPGs) on cell surfaces. Researchers believe this disrupted binding prevents the downstream cascade of tau spreading and neurodegeneration that APOE normally facilitates.
The case was electrifying for the field. It demonstrated that modifying APOE could provide robust protection against Alzheimer's even in the presence of overwhelming amyloid pathology. It also expanded the therapeutic playbook beyond the APOE4-to-APOE2 strategy: perhaps introducing the Christchurch mutation via gene editing could offer an alternative or complementary protective effect.
In 2023, Dr. Joseph Bhatt and colleagues at the Banner Alzheimer's Institute and other institutions published follow-up research showing that the Christchurch mutation's protective mechanism involves reduced APOE binding to HSPGs, which in turn limits the uptake and spread of pathological tau. Animal studies confirmed that introducing the Christchurch mutation into APOE reduced tau-mediated neurodegeneration in mouse models.
"The Christchurch case was a turning point," said Dr. Yakeel Quiroz, a neuropsychologist at Massachusetts General Hospital who has spent years studying the Colombian kindred. "It showed us that the brain can tolerate enormous amyloid burden if tau pathology is kept in check — and that APOE is a key lever for controlling that process."
Amyloid Antibodies vs. Gene Editing: Treatment vs. Prevention
To appreciate why gene editing for Alzheimer's matters, it helps to understand the current state of treatment and why existing approaches, while significant, remain profoundly limited.
The Amyloid Antibody Era
After decades of failure, two anti-amyloid antibodies have finally demonstrated clinical efficacy in large Phase 3 trials:
Lecanemab (Leqembi), developed by Eisai and Biogen, was granted full FDA approval in July 2023. In the CLARITY AD trial of 1,795 patients with early-stage Alzheimer's, lecanemab reduced the rate of cognitive decline by 27% over 18 months compared to placebo. It substantially cleared amyloid plaques from the brain.
Donanemab, developed by Eli Lilly, showed a 35% slowing of decline in its TRAILBLAZER-ALZ 2 trial among patients who started treatment early and had lower levels of tau pathology. The FDA approved donanemab in 2024.
These results were hailed as proof that the amyloid hypothesis has merit and that removing amyloid from the brain can modestly slow cognitive decline. But the enthusiasm has been tempered by sobering realities:
- The benefit is modest. A 27-35% slowing of decline, while statistically significant, translates to a difference of roughly 4-7 months of preserved function over 18 months. Many patients and caregivers cannot perceive the difference in daily life.
- The risks are real. Both drugs cause amyloid-related imaging abnormalities (ARIA), including brain swelling (ARIA-E) and microhemorrhages (ARIA-H). ARIA occurs in 20-35% of patients and is more common and more severe in APOE4 carriers — precisely the population at highest risk. Several deaths linked to ARIA have been reported.
- The treatment is burdensome. Both drugs require biweekly or monthly intravenous infusions at specialized centers, along with regular MRI monitoring. Lecanemab costs approximately $26,500 per year before infusion costs.
- They work only in early disease. By the time most patients are diagnosed, substantial neuronal loss has already occurred. Removing amyloid at that stage is like removing matches from a building that has already burned down.
Why Prevention Makes More Sense
The fundamental insight driving the gene editing approach is that Alzheimer's is a disease of prevention, not treatment. By the time clinical symptoms appear, an estimated 20-30 years of pathological changes have already occurred in the brain. Amyloid accumulation begins in the mid-forties or earlier in APOE4 carriers. Tau pathology follows. Synaptic loss and neuronal death are irreversible.
Gene editing offers something that no existing therapy can: the possibility of intervening before the pathological cascade begins. An APOE4 carrier who receives a base editing treatment in their forties — converting their APOE4 alleles to APOE2 — could potentially avoid developing Alzheimer's altogether. Not a 27% slowing of decline. Not a few extra months. Prevention.
This is not wishful thinking. The epidemiological data from natural APOE2 carriers, the Christchurch case, and the preclinical editing results all point toward the same conclusion: modifying APOE can provide potent, durable protection against Alzheimer's pathology and cognitive decline.
"We've spent thirty years trying to treat Alzheimer's after the damage is done," observed Dr. Eric Topol, founder and director of the Scripps Research Translational Institute. "Gene editing gives us a real chance to prevent it. That's a completely different paradigm."
Academic Research Programs Pushing the Field Forward
Several major academic institutions are actively pursuing gene editing strategies for Alzheimer's and related neurodegenerative diseases.
The Broad Institute of MIT and Harvard remains the epicenter of base editing technology, with David Liu's laboratory continuing to refine adenine and cytosine base editors for improved efficiency, specificity, and deliverability. Collaborations between the Liu lab and Alzheimer's researchers are exploring APOE editing as well as other genetic targets, including the protective Icelandic APP mutation (A673T), which reduces amyloid-beta production and has been associated with reduced Alzheimer's risk even in non-carriers when introduced via editing.
The Gladstone Institutes and UC San Francisco, under the leadership of Yadong Huang, have been pioneers in understanding APOE4's neurotoxic mechanisms and were among the first to demonstrate APOE4-to-APOE3 conversion using CRISPR in human iPSC-derived neurons. Their work has shown that converting APOE4 to APOE3 rescues multiple disease-associated phenotypes in cell models, including deficits in lipid metabolism, endosomal trafficking, and synaptic function.
Stanford University has contributed advances in both AAV capsid engineering for brain delivery and in understanding the neurobiology of APOE variants. The laboratory of Dr. Tony Bhatt and collaborators have developed novel animal models for testing APOE editing strategies in the context of tau pathology.
MIT's Picower Institute for Learning and Memory has been at the forefront of understanding how Alzheimer's pathology disrupts neural circuits and how genetic interventions might restore normal brain function. Their work on gamma oscillation entrainment and neuroinflammation has provided additional context for how APOE editing might protect brain health.
The UK Dementia Research Institute at University College London has launched programs exploring both CRISPR-based and antisense oligonucleotide approaches to modifying APOE expression in the brain, with an emphasis on translational readiness and clinical trial design.
Ethical Questions: Editing Genes Before Symptoms Appear
The prospect of gene editing for Alzheimer's prevention raises ethical questions that the field must confront honestly.
Predictive Genetic Testing and the Right Not to Know
If APOE4-to-APOE2 editing becomes a viable prevention strategy, who would be offered the treatment? The most obvious candidates are APOE4 homozygotes, who face an 8-12-fold increased risk. But identifying these individuals requires genetic testing — and genetic testing for Alzheimer's risk is fraught with psychological and social complexity.
Many people do not want to know their APOE status. Learning that you carry two copies of APOE4 does not mean you will definitely develop Alzheimer's — it is a risk factor, not a deterministic mutation — but the knowledge can provoke profound anxiety, depression, and altered life planning. The Genetic Information Nondiscrimination Act (GINA) prohibits discrimination based on genetic information in health insurance and employment, but gaps remain in areas like long-term care insurance and life insurance.
If a preventive gene editing treatment exists, the calculus around genetic testing changes. Knowing your APOE status would no longer be merely informational — it would be actionable. This could drive a massive increase in demand for APOE testing, with all the counseling and support infrastructure that would require.
Irreversibility and Informed Consent
Gene editing is permanent. Unlike a drug that can be discontinued if side effects emerge, a base edit to APOE cannot be undone. This raises the bar for informed consent enormously, particularly when treatment is proposed for healthy individuals who may never develop Alzheimer's regardless of their genotype.
APOE4 carriers have an elevated risk, but most APOE4 heterozygotes will not develop Alzheimer's. Offering an irreversible genetic modification to someone who might never have become sick requires a careful weighing of potential benefit against the small but nonzero risk of adverse effects from the editing procedure itself — including off-target edits, delivery-related toxicity, or unforeseen long-term consequences.
Equity and Access
Alzheimer's disease disproportionately affects Black and Hispanic Americans, who are approximately 1.5-2 times more likely to develop dementia than white Americans. These disparities reflect a complex intersection of genetic, socioeconomic, and healthcare access factors. APOE4 prevalence also varies by ancestry — it is more common in African-ancestry populations.
If gene editing treatments are developed and priced at levels comparable to other gene therapies ($500,000 to $2 million per treatment), the risk of exacerbating existing health disparities is real. The populations most burdened by Alzheimer's could be the last to access a prevention technology. Ensuring equitable access must be a priority from the earliest stages of clinical development.
Timeline to Human Trials
Where does gene editing for Alzheimer's stand on the path to human testing?
As of late 2025, no clinical trial of gene editing specifically for Alzheimer's disease has begun. The field is in the late preclinical and early translational phase. However, several factors suggest that human trials could begin within the next five to seven years.
Delivery technology is advancing rapidly. The success of AAV-based gene therapies for other neurological conditions (Zolgensma for SMA, now in the market since 2019) and the ongoing development of brain-penetrant AAV capsids and LNPs provide a technical foundation.
Base editing has proven safe in humans. Clinical trials of base editing for other conditions — notably sickle cell disease (via Beam Therapeutics) and familial hypercholesterolemia (via Verve Therapeutics, now part of Eli Lilly) — are generating safety data that will inform the design of brain-directed editing programs.
Regulatory pathways are being established. The FDA has shown willingness to consider gene editing therapies under accelerated approval and breakthrough therapy designation frameworks. For a disease as devastating and poorly treated as Alzheimer's, there is strong motivation from both regulators and patient advocacy groups to expedite development.
Biomarker advances enable earlier detection. Blood-based biomarkers for amyloid (p-tau217, A-beta 42/40 ratio) now allow identification of Alzheimer's pathology years or decades before symptoms. These biomarkers could be used to identify high-risk APOE4 carriers who are already accumulating amyloid, providing a clear rationale for early intervention and a measurable endpoint for clinical trials.
A realistic timeline might look like this: IND-enabling studies and GMP manufacturing in 2026-2028, Phase 1 safety trials in a small cohort of high-risk individuals (likely APOE4 homozygotes with biomarker evidence of early amyloid accumulation) beginning around 2028-2030, and larger efficacy trials extending into the 2030s.
This timeline is slow by the standards of patients and families who need help now. But it reflects the extraordinary care required when introducing an irreversible genetic change into the human brain.
Beyond APOE: Other Gene Editing Targets for Alzheimer's
While APOE4 editing is the most advanced and most discussed strategy, it is not the only genetic target under investigation.
The Icelandic APP Mutation
In 2012, researchers in Iceland discovered a rare variant of the APP gene (A673T) that reduces amyloid-beta production by approximately 40% and protects carriers against Alzheimer's disease and age-related cognitive decline. Carriers of this mutation who reach old age maintain better cognitive function than non-carriers, even in the general population.
Introducing this protective APP mutation via base editing could, in theory, reduce amyloid-beta production throughout the brain. The A673T variant alters the beta-secretase cleavage site on APP, making it a less efficient substrate for the enzyme that initiates amyloid-beta generation. This approach is complementary to APOE editing and could be pursued in parallel or in combination.
TREM2 and Microglial Function
TREM2 is a receptor on microglia — the brain's resident immune cells — that plays a critical role in clearing amyloid plaques and dead neurons. Loss-of-function variants in TREM2 significantly increase Alzheimer's risk. Enhancing TREM2 function through gene editing or gene addition could boost the brain's natural ability to clear pathological proteins.
Tau-Related Targets
While most genetic strategies have focused on amyloid, the correlation between tau pathology and cognitive decline is stronger than the correlation with amyloid. Editing genes involved in tau phosphorylation, aggregation, or spreading — such as MAPT (the tau gene itself) or genes involved in the cellular machinery that propagates tau pathology — represents another frontier.
The Bigger Picture: From Reactive Medicine to Genetic Prevention
The application of gene editing to Alzheimer's disease is part of a broader revolution in how we think about chronic, age-related diseases. For most of medical history, we have waited for diseases to develop and then tried to treat them. This reactive model has its place, but for diseases that begin decades before symptoms — Alzheimer's, cardiovascular disease, many cancers — it means we are always fighting from behind.
Gene editing offers the possibility of genetic prevention: identifying individuals at high genetic risk and modifying the genes responsible before disease processes take hold. This approach does not require understanding every aspect of a complex disease's pathophysiology. It requires identifying a genetic lever — a single gene variant whose modification can substantially change disease trajectory — and having the tools to pull it safely.
For Alzheimer's, APOE4 is that lever. The human genetics are unambiguous. The preclinical data are supportive. The editing tools exist. The delivery technology is catching up.
What This Means for Patients and Families
If you or someone you love is living with Alzheimer's disease today, the gene editing strategies described in this article will not arrive in time. That is a painful truth, and it must be stated plainly. Current patients need the best available care now — access to existing treatments, clinical trials, caregiver support, and compassionate end-of-life planning.
But for the next generation — for people in their twenties, thirties, and forties who carry APOE4 and wonder if they will share their parent's or grandparent's fate — the trajectory of the science offers genuine, evidence-based hope. Not hype. Not a miracle cure announced in a press release. But the steady accumulation of genetic knowledge, engineering capability, and clinical experience that could make Alzheimer's prevention a reality within their lifetimes.
The road ahead is long and uncertain. Delivery challenges must be solved. Safety must be established over years of careful clinical testing. Ethical frameworks must ensure that genetic prevention is offered equitably and with full respect for individual autonomy. None of this will happen overnight.
But for the first time in the history of Alzheimer's research, the question is no longer whether we can identify the genetic roots of the disease. The question is whether we can summon the scientific rigor, the financial investment, and the societal will to act on what we already know.
The answer to that question will determine whether the next generation inherits Alzheimer's — or edits it out of their future.
Sources
-
Alzheimer's Association. "2024 Alzheimer's Disease Facts and Figures." Alzheimer's & Dementia 20, no. 3 (2024). https://www.alz.org/alzheimers-dementia/facts-figures
-
Corder, E.H., et al. "Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families." Science 261, no. 5123 (1993): 921-923. https://doi.org/10.1126/science.8346443
-
Arboleda-Velasquez, J.F., et al. "Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report." Nature Medicine 25 (2019): 1680-1683. https://doi.org/10.1038/s41591-019-0611-3
-
Liu, D.R., et al. "Programmable base editing of A-T to G-C in genomic DNA without DNA cleavage." Nature 551 (2017): 464-471. https://doi.org/10.1038/nature24644
-
van Dyck, C.H., et al. "Lecanemab in Early Alzheimer's Disease." New England Journal of Medicine 388 (2023): 9-21. https://doi.org/10.1056/NEJMoa2212948
-
Sims, J.R., et al. "Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial." JAMA 330, no. 6 (2023): 512-527. https://doi.org/10.1001/jama.2023.13239
-
Jonsson, T., et al. "A mutation in APP protects against Alzheimer's disease and age-related cognitive decline." Nature 488 (2012): 96-99. https://doi.org/10.1038/nature11283
-
Lin, Y.T., et al. "APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer's Disease Phenotypes in Human iPSC-Derived Brain Cell Types." Neuron 98, no. 6 (2018): 1141-1154. https://doi.org/10.1016/j.neuron.2018.05.008
-
Deverman, B.E., et al. "Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain." Nature Biotechnology 34 (2016): 204-209. https://doi.org/10.1038/nbt.3440
-
Belloy, M.E., et al. "A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward." Neuron 101, no. 5 (2019): 820-838. https://doi.org/10.1016/j.neuron.2019.01.056
-
Huang, Y., and Bhatt, R. "Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy." Nature Reviews Neurology 15 (2019): 501-518. https://doi.org/10.1038/s41582-019-0228-7
-
World Health Organization. "Dementia Fact Sheet." (2023). https://www.who.int/news-room/fact-sheets/detail/dementia
